Fueling Viking Therapeutics upside, analysts at Canaccord initiated coverage of the obesity treatment stock with a buy rating, and a price target of $106 a share With a short interest of 25%, Lemonade ...
High short interest can help investors identify potential high risks. And, it can also be a sign of a possible short squeeze situation – especially if the stock in question has been rocketing higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results